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Abstract

The aim of this study was to determine aspects of the clinical usefulness of the MerrillPalmer-Revised Scales of Development (M-P-R) in children diagnosed with Autistic Disorder
(AD). The revised developmental measure reports strong levels of reliability and validity in a
standardization sample. While some clinical subsamples were included to help establish the
test’s validity, the group of children with an Autism Spectrum Disorder (ASD) was limited to a
sample size of 14. The present study recruited 50 children with Autistic Disorder (41 male, 9
female) ranging in age from 40 months to 78-months, along with a matched non-clinical sample
that was obtained from the M-P-R standardization data. Each group’s performance was obtained
from the Cognitive Battery, Gross Motor Battery, and supplemental language and parent rating
forms. Observations were also made to the special groups outlined in the M-P-R Manual. The
results suggested that the M-P-R is a tool sensitive in identifying developmental delay, but not
specific in differentiating among children diagnosed with AD and other common early childhood
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disorders. In part, the large variability in test performance across the AD sample contributed to
this diagnostic weakness.
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Chapter 1
Introduction
Neurodevelopmental Disorders
Autism Spectrum Disorders (ASDs) are recognized as a group of neurodevelopmental
disorders with phenotypic behaviors evident in early childhood development (Newsom &
Hovanitz, 2006). At the present time, this group is classified under Pervasive Developmental
Disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM; DSM,4th ed., text
revision; DSM-IV-TR (American Psychiatric Association [APA], 2000) and defined as severe
and pervasive impairment in several areas of development. This includes reciprocal social
interaction skills, communication skills, and stereotyped behavior, interests, and activities.
Among the diagnoses within this category are Autistic Disorder (AD), Asperger’s Disorder,
Rett’s Disorder, Childhood Disintegrative Disorder (CDD), and Pervasive Developmental
Disorder Not Otherwise Specified (PDD NOS). Researchers suggest that Rett’s Disorder and
CDD are diagnosed in far fewer cases when compared to Autistic Disorder (1:10,000 for Rett’s
and <1:50,000 for CDD; Kozinetz, Skender, MacNaughton, Aimes, Schultz, Perus, & Glaze,
1993). As such, when the term Autism Spectrum Disorder (ASD) is employed it is referring to a
diagnosis of AD, Asperger’s Disorder, or PDD, NOS; diagnoses with overlapping symptoms and
etiology occurring along a continuum (Luyster, Kadlec, Carter, & Flusberg, 2008). Proposed
revisions for the (DSM-V; APA, 2011) suggest that the term Pervasive Developmental Disorders
will be changed to a single diagnostic category known as Autism Spectrum Disorders to increase
the specificity of the diagnosis (APA, 2011). Currently, ASDs are recognized to be more
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prevalent in childhood than diabetes, cancer, and spina bifida (Filipek et al., 2000; Centers for
Disease Control [CDC], 2012). In addition to advances in early diagnosis the increase in
prevalence may be due to an increased awareness of the etiology of ASDs on the part of both the
general public and health care providers (Volkmar, Lord, Bailey, Schultz, & Klin, 2004).
Etiology and Common Symptoms
ASDs are understood to be a neurological disorder that affects the way the brain processes
information, subsequently impairing behavioral development (Brimacombe, Pickett, & Pickett,
2007; Campbell, Schopler, Cueva, & Hollin, 1996). Severe impairment in social communication
skills such as joint attention, shared affect, eye-contact, conventional and symbolic gestures, and
skills associated with functional and symbolic play have been found to be consistent in preschool age children diagnosed with an ASD (Veness et al., 2012). Numerous studies have also
identified children with ASDs demonstrate greater difficulty in imitation skills, empathic
responding, a disinterest in other children, and an absence in range of facial expressions when
compared to children identified with varying developmental delays (Charman et al., 1998;
Landry & Loveland, 1988; Lord, 1995; Rogers, Hepburn, Stackhouse, & Wehner, 2003;
Trillingsgaard, Sorensen, Nemec, & Jorgensen, 2005. Furthermore, a delay or deficit in language
acquisition was also found to be a common symptom in children identified with an ASD
(Luyster, Kadlec, Carter, Tager-Flusberg, 2008). Research suggests that the level at which a
child has the ability to express language by preschool age would determine his/her diagnosis on
the autism spectrum (Kobayashi, Murata, Yoshinaga, 1992; Venter, Lord & Schopler, 1992; as
cited in Lord et. al., 2000).
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De Giacomo & Fombonne (1998) found that parents presented concerns regarding their
child’s development and behavioral presentation to a primary care provider when the child was
approximately 17- months of age. Most notably was the child’s failure to utter his or her “first
words” and phrases. Conversely, the average age a child receives a definitive ASD diagnosis is
approximately at the age of four-years or beyond (De Giacomo & Fombonne, 1998).
Prevalence
The CDC division of Autism and Developmental Disabilities Monitoring Network
(ADDM) surveyed multiple areas of the United States and identified a rate of 1:88 eight-year-old
children diagnosed with an ASD in 2008 (CDC, 2012). This has increased from the 2002 data
which indicated a rate of 1:156 eight-year-old children. Although the surveillance summaries are
exclusive to 14 specific sites, it is feasible to state that there has been a general increase in
known cases of ASDs across the nation.
The increased rates of ASDs reinforce the necessity for precise diagnostic measures to
ensure individually tailored intervention plans. Harris and Handleman (2000) have proposed that
early detection of an ASD and subsequent early intervention can have a positive effect on
prognosis. These effects include improved language skills, social relationships, adaptive
functioning, and fewer maladaptive behaviors; all of which increase the opportunity of
successful classroom inclusion. Unfortunately, determining a differential diagnosis can be
difficult in very young children.
Diagnostic Difficulties
The behaviors in children with developmental delays or language delays demonstrate
impaired social skills, resembling behaviors similar to a child with an ASD (Charman et al.,
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1998; Cox, et al., 1999. Lord, 1995; Lord, Risi, et al., 1993). Although genetic research has
advanced in regards to specific markers for autism susceptibility, current tests to determine an
ASD diagnosis is not available. As such, diagnosis is weighted heavily upon clinical observation
and parental report (Norbury & Sparks, 2012). Furthermore, the comorbidity of an ASD and
intellectual disability has complicated the diagnostic process (Hartley & Sikora, 2010).
The DSM-IV-TR (APA, 2000) recognizes that intellectual disability (formerly known as
mental retardation; ranging from mild to profound) may be associated with autism. Edelson
(2006) surveyed 215 articles published between 1937 and 2003 in order to clarify previous
indications that nearly 70% of individuals with a diagnosis of an ASD also met criteria for
intellectual disability. Her findings suggested that approximately 50% of the cases were found to
meet criteria for an ASD diagnosis and intellectual disability. Continued empirical evidence is
necessary to determine the current prevalence rate of autism and intellectual disability. Corbett &
Gunther (2011) suggest the importance of a comprehensive autism evaluation (which includes a
measure of cognitive functioning) in order to fully understand an individual’s ability level and
aid in diagnostic clarification. However, if the language demands of the diagnostic measure are
greater than the ability of the child with suspected ASD, then the assessment results may not be
representative of the child’s true abilities. Research suggests that children with ASDs are more
socially competent, less anxious, and more flexible when the language demands are lowered to
their level of ability (Mesibov, Schopler, & Hearsey, 1994; as cited in Lord, Risi, et al., 2000). In
response to this, the need for a diagnostic measure in which the language demands are minimal
may offer a more accurate estimation of a child’s ability and subsequently provide a guide for the
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appropriate treatment interventions. Conversely, an inaccurate diagnosis would likely result in
lost opportunities for specialized, early intervention (Coonrad & Stone, 2005).
Evaluation and Diagnosis
Numerous diagnostic measures are used in a variety of settings to determine a child’s
ASD. These include, but are not limited to, criteria set forth by the DSM-IV-TR (APA, 2000), the
Autism Diagnostic Observation Schedule-Generic (ADOS-G; Lord, Rutter, DiLavore, & Risi,
2000), the Autism Diagnostic Interview-Revised (ADI-R; Rutter, Le Couteur, & Lord,2003) the
Childhood Autism Rating Scale (CARS; Schopler, Reichler, & Renner, 1988), and the Vineland
Adaptive Behavior Scales – Second Edition (Sparrow, Cicchetti, & Balla, 2005). Measures of
cognition include the Wechsler Intelligence Scales for Children (WISC-IV; Wechsler, 2003) and
the Stanford Binet- Fifth Edition (SB-5; Roid, 2003). Measures frequently used with young
children and children unable to basal on the aforementioned measures include the Mullen Scales
of Early Learning (Mullen, 1995) and the Bayley Scales of Infant Development, Third Edition
(Bayley – III; Bayley, 2005). Despite the above instruments being utilized in a variety of
educational and clinical settings, they are typically used in the initial diagnostic testing phase
rather than in monitoring progress or as outcome measurement (Roid, & Sampers, 2006).
Researchers in special education have called for there to be a stronger link between assessment
measures and early intervention (Bagnato, Neisworth, & Munson, 1989; Meisels & Fenicel,
1996). In the same manner, research suggests that early intervention (between the ages of 18
months and 4 years) in children with autism often results in improvements of language,
communication and cognition (Rogers & Vismara, 2008).
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Individuals with Disability Education Act
The Individuals with Disabilities Education Act (IDEA; IDEA, 1990, 1997) is a law
requiring specific services to be made available to children with disabilities. The specific
services identified by the IDEA should be tailored to meet the needs of the child as indicated by
an Individualized Education Plan (IEP) within academic settings (retrieved from http://www
.autism-society.org/site/edu Oct 2008). The IEP identifies the special education plan outlining
goals for the academic school year, the services needed to help meet those goals (i.e., speech,
occupational, or physical therapy; specific area of academic assistance, etc.), and a method of
evaluating progress within the least restrictive environment. The IDEA oversees how states and
public agencies provide early intervention, special education and related services to over 6.5
million infants, toddlers, children and youth who meet eligibility requirements. IDEA is
separated by two divisions to better assist children and their families. IDEA Part C serves
children ages birth to 2 years, and IDEA Part B services children and youth ages 3-21. Under the
IDEA legislation, the use of a progress monitoring assessment is vital for the verification of
response to intervention (RTI). Which in turn, is the monitoring of treatment plans to ensure the
child is responding to interventions identified by his/her strengths and weaknesses. The need for
accurate and repeatable screening measures becomes more evident as the number of children
with ASDs needing services continues to rise.
Merrill-Palmer-Revised Scales of Development
The Merrill-Palmer-Revised Scales of Development (M-P-R) was revised by Roid and
Sampers (2004) to update and expand the original Merrill-Palmer-Scales (Stutsman, 1931) in
order to meet the requirement established by federal and state legislation for early identification
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of developmental delays and learning difficulties in children. It is an individually administered
standardized measure of developmental functioning in young children from birth through 78
months. The M-P-R was designed to be used as a repeat measure to provide progress monitoring
(skill mastery) within the areas addressed by the IDEA.
The unique structure of this predominately non-verbal, play based assessment allows for
early identification of developmental delays, the assessment of pre-term infants, provides
measurement of small increments of improvement in development, has a reliable and valid scale
of development for children with limited expressive language ability, and aids with individual
treatment planning for children with developmental delays (Roid & Sampers, 2004).
Early identification of developmental delays in the areas of cognitive, language, and
motor assessments is essential for children who may later qualify for services under IDEA.
Screening with a reliable preschool test can be efficient and cost effective when followed by
comprehensive intervention planning (Gregory, 1996). The M-P-R also satisfies the need for
evaluating small increments of progress. Unlike the Bayley Scales of Infant Development-Third
Edition (Bayley, 2005), the M-P-R tasks were designed to measure the quality of performance as
a child develops rather than the broad achievement of developmental milestones (Roid &
Sampers, 2004). By utilizing a predominately non-verbal assessment, the likelihood of obtaining
a more accurate ability assessment of children with ASDs increases.
Scales
The M-P-R includes four assessment components: (a) Cognitive Battery which assesses
Cognitive, Fine Motor, Receptive Language scales, in addition to supplementary scores for
Memory, Speed and Visual-Motor ability; (b) Gross Motor Development which assesses gross
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motor, unusual movements, and atypical movement patterns; (c) Parent Rating Forms which
assess Social-Emotional Development, Social-Emotional Temperament, and Self-Help/Adaptive
Behaviors; 4) Supplemental examiner and parent rating scale to assess Expressive Language.
Please refer to Appendix A for test item examples.
Test Construction
The M-P-R utilizes the hierarchical model formulated by the Cattell-Horn-Carroll (CHC)
theory of cognitive abilities. Table 1 displays the CHC model as identified in chapter one of the
M-P-R technical manual (McGrew & Woodcock 2001; as cited in Roid & Sampers, 2004).
Stratum I is the general intelligence or “g” factor. Stratum II identifies seven broad factors,
which include fluid and crystallized factors and represent the hierarchical nature of cognitive
factors (Roid, Shaughnessy, & Greathouse, 2005). Stratum III includes the “sub-skills” of
intelligence. Roid et. al. (2005) state that the benefit of the CHC theory fulfills two concepts “(a)
the multifaceted nature of intelligence and (b) the benefit of using individual subtests across
batteries to measure theory-based cognitive factors” (p. 496). Additionally, the M-P-R includes
an optional scoring system (sensitive to change) referred to as Rasch analysis. As outlined in the
Manual: The “growth scores” used in the M-P-R are a linear transformation of the values
produced by the Rasch model. This model predicts both the ability of the child and the difficulty
of the items and allows for the child’s ability to be positioned on an interval scale. This approach
provides a “map” that can aid in treatment planning and depict a more precise view of the
abilities in a child with disabilities. Specifically with the M-P-R, items missed below the child’s
overall ability level can be used to target intervention by identifying skills to be as well as
determining the instructional ability level of the child (Roid & Sampers, 2004, p. 247).
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Table 1
Cattell-Horn-Carroll Model of Cognitive Abilities and the Abilities Measured in the M-P-R
Stratum I

Stratum II

Stratum III

Fluid Reasoning (gF)

General Ability (“g” factor)

Crystallized Ability (gC)

Spatial Rotations (SR)

Short-term Memory (gSM)

Visualization (VZ)

Visual Spatial (gV)

Visual Memory (VM)

Auditory Processing (gA)

Closure Flexibility (CF)

Long-term Retrieval (gLR)

Length Estimation (LE)

Processing Speed (gS)

As stated in Roid and Sampers (2004), Rasch-based scores have been used on other
published tests to obtain age equivalences including all of the editions of the Woodcock-Johnson
Psychoeducational Battery (Woodcock & Johnson, 1977; 1989;Woodcock, McGrew & Mather,
2001), the Leiter-R (Roid & Miller, 1997), and the Stanford Binet Intelligence Scales, Fifth
Edition (SB5, Roid, 2003).
Reliability
Reliability results for each of the domains assessed by the M-P-R are provided in the
technical manual (Roid & Sampers, 2004) including internal consistency, test-retest reliability,
and standard errors of measurement. Both classical test theory and item response theory (IRT)
approaches were employed. Internal consistency values across age groups for the Developmental
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Index was found to be .98, Cognitive .94, Receptive Language .94, Fine Motor .91, Memory .77,
Speed .77, and Visual Motor .91.
As stated in the M-P-R technical manual:
Each of the scales spans a large range of ages, but each estimate was calculated on the
children within the designated age group of normative sample. Thus, the reliability
estimates are not inflated by developmental growth, as they would if calculated on the
entire normative sample (Roid & Sampers, 2004, p. 127).
The internal consistency estimates for Gross Motor Battery, the Social-Emotional Scale,
Self-Help/Adaptive and the Language scales are averaged across age groups. The average
reliability for the Gross Motor Battery is .93. Social-Emotional Development Index is .93, SelfHelp/Adaptive .94, Language .98, and Expressive Language, .97.
The Cognitive Battery Scales Standard Error of Measurement varies within the domains.
The Developmental Index SEM ranges from 2.12-2.60, Cognitive ranges from 3.00-4.24,
Receptive Language ranges from 3.00-4.50, Fine Motor ranges from 3.67-5.71, Memory ranges
from 6.00-8.26, Speed ranges from 6.00-8.26, and Visual Motor ranges from 3.35-6.36.
Conventional Standard Errors of Measurement for the Gross Motor Battery range from 3.004.74, Social-Emotional Development ranges from 3.67-4.74, Self-Help/Adaptive ranges from
3.67-3.97, Language Total ranges from 2.12-2.60, and Expressive Language ranges from 2.603.00.
The Test-retest reliability coefficients depict little change from the first test
administration to the second administration, which were three weeks apart. Correlation for the
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Developmental Index is .89, Cognitive .87, Receptive Language .90, Fine Motor .90, Visual
Motor .90, Speed .84, Memory .89, Gross Motor .88, Social-Emotional .89, and Self-Help .84.
Validity
The authors of the M-P-R extensively field tested content and construct validity. Cross
battery correlations with the Bayley Scales of Infant Development (Bayley, 2005), StanfordBinet 5th Edition (Roid, 2003), and Leiter-R (Roid & Miller, 1997) were used to verify the
existence of expected construct and content dimensions.
The authors state:
content-related evidence of validity was established by a combination of careful
item-response theory analysis; item selection or item development based on
review of the literature; scaling verification (to establish consistency with
development theory); expert review, and empirical studies of internal consistency
(Roid & Sampers 2004, p. 137).
Means, standard deviations, and standard score correlations were calculated between
performance on the M-P-R and the Bayley Scales of Infant Development, 2nd Edition Mental
Scale (Bayley, 1993). The Bayley is the most widely used developmental instrument in North
America and the correlation that exists with the M-P-R provides strong criterion-related evidence
of validity (Roid & Sampers 2004). The correlation between the Bayley Mental Scale and the MP-R four cognitive domains were strong. The Developmental Index of is .92, Fine Motor is .86,
Receptive Language is .92, Expressive Language is .98, and Memory scores is .85.
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The M-P-R demonstrates consistent evidence of validity from content-analysis studies
with extensive item analysis data. Criterion-related studies showed excellent results for
concurrent correlations and the classification accuracy in identifying cognitive delays.
Clinical Utility
Sattler (2001) described clinical utility as, “the extent to which a test agrees with a
criterion measure in classifying individuals as to their membership in a category” (p 116). To
determine the clinical utility of the M-P-R in children suspect of an ASD, further investigation is
necessary. Because this measure is play based and less language dependent than other
developmental measures it may be beneficial for children with ASD. The M-P-R may assist in
the development of appropriate treatment planning which would increase the significance of
early intervention. This study investigated important aspects related to the validity of the M-P-R
and its ability to identify skill sets in children who have been previously identified with AD.
Published research for the M-P-R is limited to the try-out edition which included data on the
general population and several clinical populations detailed in the testing manual. Fourteen
children with an unspecified ASD (aged 36 to 75 months) were administered the M-P-R.
Unfortunately, limited information is provided on autism symptom severity or a discussion
differentiating their abilities from a non-clinical sample. Furthermore, because the normative
sample utilized a group comprising ASDs rather than one specific diagnostic criterion (i.e., AD)
the skill levels represent a broad range of functioning levels.
Study Purpose and Hypotheses
This study assessed important aspects related to the clinical utility of the M-P-R in the
assessment of children diagnosed with Autistic Disorder. It was hypothesized that this instrument
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would demonstrate consistent aspects of a psychometrically sound measure for estimating
cognitive abilities. An independent analysis of the criterion related validity was performed within
a population of children diagnosed with AD. Collectively, this group has demonstrated difficulty
performing on more traditional language based measures of intelligence (Tsatsanis et al., 2003).
Research indicates that children with developmental delays appear more socially competent, less
anxious, and more flexible in situations where the language demands are low (Mesibov,
Schopler, & Hearsey, 1994). Because the M-P-R was designed to minimize language demands it
was presumed that children with AD would have a greater chance of participation and thereby
provide a representation of their true abilities. The profiles of the M-P-R Cognitive Battery,
Gross Motor Scale, Language Scales, Social-Emotional Development and Self-Help/Adaptive
Behavior parent rating forms were observed in children diagnosed with AD. It was hypothesized
that children with Autistic Disorder would obtain different scores and thereby the battery would
be shown to discriminate between a non-clinical group and several clinical groups previously
identified during the standardization of the M-P-R (i.e., cognitive delay, premature infants,
speech and language delay, deafness, and severe motor delay).
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Chapter 2
Method
Participants
The participants for this study were obtained from either a parent study conducted within
the Children’s Development and Rehabilitation Center (CDRC) at Oregon Health and Science
University (OHSU) or from the greater Portland, Oregon area. The OHSU participants were
those seen by a multidisciplinary team evaluation through the Autism Clinic at OHSU and who
had agreed to be involved in a study investigating cholesterol metabolism in children diagnosed
with Autistic Disorder. This OHSU study was also investigating correlations between
neurocognitive/neurobehavioral variables and sterol metabolism. The M-P-R was one of the
measures used to assess cognitive abilities of young children (under the age of 6) in that larger
study. The subsample examined in this study included 50 children ages 3-years, 4-months
through 6-years, 6-months of age (M = 5.1 years, SD = 10.2) who had been diagnosed with
Autistic Disorder according to the DSM-IV-TR diagnostic criteria either by a multidisciplinary
assessment team at OHSU or by a private developmental pediatrician. The DSM-IV-TR (APA,
2000) criteria are found in Table 2. Please refer to Appendix B for an example of the diagnostic
checklist. Participants were excluded if the child’s age exceeded 6-years, 6-months at time of
testing, if the child had a co-morbid genetic disorder such as Down Syndrome, Rett’s Disorder,
Fragile X Syndrome, or were diagnosed with Pervasive Development Disorder Not Otherwise
Specified or Asperger’s Disorder. Children diagnosed with Mental Retardation or Global
Developmental Delay were not disqualified. Additionally, for each child included, the Total
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Table 2
DSM-IV-TR Diagnostic Criteria for Autistic Disorder
A. A total of six (or more) items from (1), (2), and (3), with at least two from (1), and one
each from (2) and (3):
(1) Qualitative impairment in social interaction, as manifested by at least two of the
following:
(a) Marked impairment in the use of multiple nonverbal behaviors such as eye-toeye gaze, facial expression, body postures, and gestures to regulate social
interaction
(b) Failure to develop peer relationships appropriate to development level
(c) A lack of spontaneous seeking to share enjoyment, interests, or achievements
with other people (e.g., by lack of showing, bringing, or pointing out objects of
interest)
(d) Lack of social or emotional reciprocity
(2) Qualitative impairments in communication as manifested by at least one of the
following:
(a) Delay in, or total lack of, the development of spoken language (not
accompanied by an attempt to compensate through alternative modes of
communication such as gesture or mime)
(b) In individuals with adequate speech, marked impairment in the ability to initiate
or sustain a conversation with others
(c) Stereotyped and repetitive use of langue or idiosyncratic language
(d) Lack of varied, spontaneous make-believe play or social imitative play
appropriate to developmental level
(3) Restricted repetitive and stereotyped patterns of behavior, interests, and activities,
as manifested by at least one of the following:
(a) Encompassing preoccupation with one or more stereotyped and restricted
patterns of interest that is abnormal either in intensity or focus
(b) Apparently inflexible adherence to specific, nonfunctional routines or rituals
(c) Stereotyped and repetitive motor mannerisms (e.g., hand or finger flapping or
twisting, or complex whole-body movements)
(d) Persistent preoccupation with parts of objects
B. Delays or abnormal functioning in at least one of the following areas, with onset prior
to age 3 years; (1) social interaction, (2) language as used in social communication, or (3)
symbolic or imaginative play.
C. The disturbance is not better accounted for by Rett’s Disorder or Childhood
Disintegrative Disorder
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Score from the Autism Diagnostic Observation Schedule (ADOS; Lord, Rutter, et al. (2000) fell
above the cut-off score for Autism Spectrum and above the cut-off score for Autism (combined
Communication total score plus the Social Interaction total score).
Following a phone conversation, 82 parents of 129 eligible children agreed to participate
in the cholesterol metabolism study. Sixty-eight children were scheduled for a blood draw and
the M-P-R assessment; however 18 of these children chose not to proceed because of the
required blood draw. Therefore, 47 completed the M-P-R.
The larger study’s investigators had hoped to enroll 80 participants and so additional
community participants were recruited thru online listings (e.g., Yahoo Autism support groups,
web forums, etc.) and flyers posted in local pediatrician, speech pathologist, and occupational
therapist offices. All community respondents were screened for eligibility using the same criteria
as enumerated above for the OHSU sample. Twelve parents responded to community
recruitment efforts; seven children met all inclusion criteria and were entered into the study;
three completed the study. This resulted in a combined sample of 50 participants, 41 (82%) of
whom were male and nine (18%) were female. Additionally, a non-clinical age matched sample
comprised of eighty children (M age = 59.6 months) was obtained from the M-P-R co-author,
Gale Roid, Ph.D. Demographic characteristics of the clinical and non-clinical samples are
provided in Table 3. Please refer to Appendix C for demographic information and Appendix D
for the consent form.
Measures
Autism Diagnostic Observational Schedule (ADOS; Lord, Rutter, et al., 2000). The
ADOS is a semi-structured, standardized, play-based measure designed to assess communication
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Table 3
Demographic Characteristics of Each Autism Subsample and a Non-Clinical Sample
Study Samples

Mean Age and (SD)
[months]
Gender (% male)
Ethnicity (%)
Caucasian
Hispanic
African-American
Asian/Pacific Islander
Other
Not self-identified

Community
Recruited
Subsample
(n = 3)

OHSU Study
Subsample

Combined
Clinical Sample

Non-Clinical
Sample

(n = 47)

(n = 50)

(n = 80)

52.3
(13.3)

60.8
(10.1)

60.4
(10.3)

59.2
(9.7)

66.6

82.9

82.0

77.5

66.7

63.8
2.1
2.1
2.1
10.6
19.1

64.0
2.0
4.0
2.0
10.0
18.0

77.5
2.5
7.5
5.0
7.5

33.3

Note. OHSU = Oregon Health and Science University

abilities and social interactions for individuals presenting with symptoms consistent with an
autism spectrum disorder. The ADOS is comprised of four modules. The module used is
determined based upon the individual’s expressive language ability. Given the age and
functioning level of the participants Modules1, 2, or 3 were used in this study. Module 4,
designed for adolescents and adults was not used during this study. Individuals received item
scores based upon an algorithm within each domain. 0 = no evidence of abnormal behavior, 1 =
abnormal behavior present but not severe, or 2 = behavior present and a degree of severity is
observed (Lord et al., 2000). Diagnostic algorithms within the domains of Communication,
Social Interaction, and a combined Communication + Social Interaction are used to determine if
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a child met criteria for Autism, Autism Spectrum, or non-autism spectrum. The inter-rater
reliabilities reported by the authors for the respective domains are: .84 for Communication, .93
for Social Interaction, and .92 for Communication+ Social Interaction. The test-retest reliabilities
for the domains are .73 for Communication, .78 for Social Interaction, and .82 for
Communication +Social Interaction .82 (Lord, Rutter, et. al. 2000).
The Merrill-Palmer-Revised Scales of Development (M-P-R; Roid & Sampers,
2004). The M-P-R is a developmental measure for ages 1 month to 78 months (6 years, 6
months). It yields a Developmental Index score which consists of the overall Cognitive Battery
score. The Cognitive Battery consists of separate domain scores for Cognitive, Fine Motor,
Receptive Language, Memory, Speed, and Visual motor skills. The M-P-R also includes
supplemental scales for Gross Motor abilities, Expressive Language abilities, and parent report
measures of the child’s Social-Emotional Development and Self-Help/Adaptive Behaviors.
Standard scores can be converted to Growth Scores to highlight strengths and weaknesses for the
purpose of intervention planning and reassessment. Information regarding the reliability and
validity of this measure is reported in Chapter 1.
Procedure
As this investigation was part of a larger OHSU study, approval from the OHSU’s
Internal Review Board (IRB) had already been obtained, and parents had already given consent
for the M-P-R testing of their children. Approval by the GFU IRB committee was also obtained
for the M-P-R component of the investigation. Once signed and dated, a copy of the consent
form was given to each child’s parent/guardian. Then the child received a standardized
administration of the M-P-R which lasted 30 to 60 minutes. During the testing, the parents and/or
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guardian were/was given the opportunity to complete all M-P-R rating scales, including the
Social-Emotional Temperament, Expressive Language, Social-Emotional Behavior and the SelfHelp/Adaptive Behavior rating forms. As was noted in the consent document, following test
completion, a $20 gift card from a local merchant was given to the participant’s family as a token
of appreciation
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Chapter 3
Results

Data were analyzed using the Statistical Package for the Social Sciences (SPSS). This
study assessed important aspects of the M-P-R Cognitive Battery, Gross Motor domain,
Expressive language domains, and the parent rating forms (Social-Emotional Development and
Self-Help/Adaptive Behavior) in the assessment of children diagnosed with AD. It was
hypothesized that this instrument would demonstrate characteristics consistent with a
psychometrically sound measure for estimating cognitive abilities when used with this
population. It was also hypothesized that the M-P-R would differentiate between a non-clinical
group and several clinical groups previously identified during the standardization of the M-P-R
(specifically, those with autism, cognitive delay, those experiencing premature births, speech and
language delay, deafness, and severe motor delay).
Demographic Characteristics
Demographic characteristics of the three samples used for this study are summarized in
Table 3. A one-way ANOVA was conducted on age across the three samples (community
recruited subsample, OHSU study subsample, and non-clinical sample) to determine if
significant age differences existed. No significant age difference was obtained (F (2, 127) = 1.21,
p = .30). Likewise, Chi- Square tests were conducted on gender and ethnicity proportions found
in Table 3. No significant gender difference was obtained ( 2 (2) = .84¸ p =.66). However,
significant ethnicity proportions were identified across the three groups ( 2 (10) = 31.72, p =
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<.001) with the Caucasian participants for both the hospital sample and the non-clinical sample
comprising a greater proportion than found with the Community sample. While there was a
difference in ethnicity proportion, any difference contributed by aggregating the community
autistic sample (n = 3) with the OHSU autistic sample (n = 47) would have negligible impact.
Plus, there is no evidence that would suggest that different ethnicities manifest autistic
symptomotology differently. The M-P-R Cognitive Battery provides an overall Developmental
Index score. An independent t-test indicated no significant M-P-R Developmental Index mean
difference between the hospital group and the community group (t (48) = 1.02, p = .31).
Therefore, it was decided that since there were no age, gender, or overall mean differences
between the community and OHSU samples, the data from these two autistic samples would be
combined; all analyses reported below reflect this pooling of the two samples.
The demographic characteristics of the two samples were analyzed. An independent t-test
indicated no age difference between the clinical sample and the non-clinical group (t (128) = .61,
p = .54). Similarly, when a Chi Square analysis between the clinical sample and the non-clinical
group was conducted, no significance in gender ( 2 (1) = .38, p = .54) resulted. Therefore, the
two groups were found to have similarly age and gender matched participants. Any differences
found between the two samples will not be attributed to age or gender.
Internal Consistency
As stated previously, the Developmental Index score is the summary score of the
Cognitive Battery of the M-P-R. Because the focus on treatment planning is typically determined
by the Developmental Index score, internal consistency among items which comprise the
Developmental Index was computed for the clinical group to determine if the items were
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consistent within the domain measured (i.e., cognitive, fine motor, receptive language, memory,
speed, and visual motor) and similar to information provided in the M-P-R Manual. Internal
consistency results for the items of the various M-P-R Cognitive Domains using an autistic
sample, have not been reported in the literature. Cronbach’s Alpha coefficients are found in
Table 4, and indicate that the test items within each respective domain have excellent internal
consistency. The internal consistency coefficients found in the M-P-R Manual (Roid & Sampers,
2004) are included in Table 5. While the age divisions are not identical, nonetheless the
reliability coefficients of the clinical sample are uniformly higher than those associated with the
standardization sample. The greatest difference in correlations can be observed in the Fine
Motor, Memory, and Speed domains. These differences may reflect the greater age range in the
non-clinical sample. Nonetheless, if a criterion is used that coefficient alpha should be at or
above .80, then for both age groups and across all of the M-P-R Cognitive Battery domains for
the clinical sample there is strong internal consistency for important decision-making.

Table 4
Internal Consistency for M-P-R Autistic Sample
Cognitive
Fine
Rec. Lang.
Memory
I = 82
Motor
I = 68
I = 27
I = 44
Chronbach’s Alpha Coefficients
Ages (months)
.98
.98
.98
.95
36-48 (n = 21)
Ages (months)
60-72 (n = 29)

.98

.97

.99

.97

Speed
I = 19

Visual
Motor
I = 41

.95

.97

.95

.96

Note. M-P-R = Merrill-Palmer-Revised Test; Rec. Lang. = Receptive Language; I = Total
number of items within each domain.
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Table 5
Internal Consistency for M-P-R Non-Clinical Sample
Cognitive
Fine
Rec. Lang.
Memory
Motor
Chronbach’s Alpha Coefficients
Ages (months)
.95
.92
.96
.84
25-48 (n = 340)

Ages (months)
49+ (n = 372)

.92

.87

.91

.74

Speed

Visual
Motor

.84

.90

.74

.82

Note. M-P-R = Merrill-Palmer-Revised Test; Rec. Lang. = Receptive Language

Validity	
  
Correlations were calculated for the clinical and non-clinical groups using the scores
obtained on the various domains of the M-P-R Cognitive Battery, including the composite
Developmental Index as well as the Gross Motor domain; results are found in Table 6. Intercorrelations for the supplemental Expressive Language domains and parent report results from
the Social-Emotional and Self Help dimensions, for both the clinical and non-clinical groups,
were also calculated and are reported in Table 7. For both tables, the AD group results are
reported in the lower left while the non-clinical group results are found in the upper right. As can
be seen in Table 6, with the exception of the Gross Motor domain, the results from the AD group
show uniformly high correlations between all 28 variables, with each respective value higher
than the corresponding value found with the non-clinical group. This would suggest, then, that,
despite their various cognitive designations, domains comprising the M-P-R Cognitive Battery
suggest a stronger inter-relationship when used with children with AD. A different finding is
noted, however, with the supplemental domains shown in Table 7. The high inter-correlations for
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the autism subsample have disappeared, except for the one correlation between Self-Help and
Social-Emotional domains which yields a highly significant correlation of .83. In summary, the
inter-correlations between the M-P-R Cognitive Battery domains and the Self-Help supplemental
parent rating scale seem to suggest greater domain similarity when assessing the skill levels of
the clinical group, compared to the non-clinical group. Alternatively, the Gross Motor,
Expressive Language, Total Language, and Social-Emotional domains appear to assess skills that
are relatively dissimilar for the clinical group.

Table 6
Inter-domain Correlations of the M-P-R Cognitive Battery for the Autistic (lower left half of the
table) and Non-Clinical (upper right half) Groups
Dev. Cog. Fine
Recep. Memory Speed Visual
Gross
Index
Motor Lang.
Motor
Motor
Dev. Index
1
.96** .77** .82**
.81**
.70** .67**
.36**
Cognitive

.97**

Fine Motor

1

.70**

.70**

.83**

.61**

.63**

.33**

.95** .91**

1

.55**

.65**

.61**

.80**

.23*

Recep. Lang.

.98** .96**

.93**

1

.60**

.60**

.48**

.25*

Memory

.97** .97**

.91**

.95**

1

.54**

.52**

.41**

Speed

.90** .87**

.97**

.89**

.86**

1

.34**

.27**

Visual Motor

.97** .95**

.98**

.96**

.94**

.93**

1

.24*

Gross Motor

.69** .66**

.70**

.66**

.66**

.67**

.70**

1

Note. M-P-R = Merrill Palmer-Revised; Dev. = Developmental; Cog. = Cognitive; Recep. =
Receptive; Lang = Language; * = p < 0.05; ** = p < 0.01.
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Table 7
Inter-domain Correlations of the M-P-R Supplemental Scales for the Autistic (lower left half of
the table) and Non-Clinical (upper right half) Groups
Expressive
Language
Social
Self-Help
Language
Total
Emotional
Expressive Language
1
.97**
.36**
.44**
Language Total

.06

1

.41**

.48**

Social Emotional

.07

.15

1

.61**

Self-Help

-.03

.28

.83**

1

Note. M-P-R = Merrill-Palmer-Revised; ** p < 0.01.

To further assess aspects related to the clinical utility of the M-P-R, it was hypothesized
that the mean standard scores obtained by the clinical group would be generally lower than the
non-clinical group. First, an Independent Samples t-test was conducted to compare the mean
standard scores of the Developmental Index for the clinical and non-clinical groups; the
respective means and standard deviations appear in Table 8, along with distribution statistics.
Results indicate that, as expected, the overall M-P-R Developmental Index score for the clinical
group (M = 62.0, SD = 37.4) was significantly lower (and with a substantially greater standard
deviation) than the non-clinical group (M = 99.6, SD = 14.4) (t (128) = -8.08, p = <.001, d =
.55). Levine’s statistic was significant (99.1, p <.001), suggesting that the subgroup variances
were not equal, although the difference between the means is substantial (almost 37 points);
given the robustness of the t-test, this result likely remains valid despite the SD differences.
While the distribution of the Developmental Index scores for the clinical group is not
significantly skewed despite what appears to be a large proportion of scores below 20 (see Figure
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1), the kurtosis statistic suggests a flat distribution. The extreme range of performance for the
clinical subgroup contributes to a rectangularly-shaped distribution. In contrast, the distribution
of the Developmental Index scores for the non-clinical group closely approximates a normal
distribution (see Figure 2). Therefore, despite what may be a change in the shape and variance of
an autism sample’s distribution, results suggest that the M-P-R Developmental Index is sensitive
in differentiating between a group of children diagnosed with AD and a non-clinical group.

Table 8
Means, Standard Deviations (in parenthesis) and Distribution Statistics for the M-P-R
Developmental Index for the Autistic and Non-Clinical Samples
Autistic
Non-Clinical
Sample (n = 50)
M-P-R Developmental Index
Skewness Statistic

M
62.0
.209

(SD)
37.4

Sample (n = 80)
M
99.6

(SD)
14.4

.03

Kurtosis Statistic

1.50

-.58

Range of scores

105

62

Minimum and Maximum

(10-115)

(70-132)

Note: M-P-R = Merrill-Palmer-Revised Test.

Next, differences between the six M-P-R Cognitive Battery domains, the Gross Motor
domain, and the supplemental domains (Expressive Language, Overall Language, SocialEmotional, and Self-Help/Adaptive Scales) for each of the groups were examined. While test
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results are complete for the children’s performance on the Cognitive Battery, Gross Motor
domain, and Expressive Language domain, the corresponding parent report measures on each
child were not provided by the parents/guardians in 17% of the autistic sample and13.8% of the
non-clinical sample. The means, standard deviations, and number of participants for the clinical
and non-clinical group domain standard scores are listed in Table 9. Figure 3 displays the
standard score distributions for both groups across each domain. Figures 4 through 14
individually illustrate the standard score distributions for each of the domains for the clinical and
non-clinical groups. The autism group obtained lower scores in each domain.
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Figure 2. Distribution of Developmental Index Scores for the Non-Clinical Sample (n = 80).

The impact of age was examined along with the domain and group variables by dividing
the sample into older and younger subgroups (using a median split). Table 10 reports the mean
scores of each age subgroup for the Cognitive Battery and the Gross Motor domain, and Table
11 reports the mean scores of each age subgroup for the supplemental domains. Interestingly, the
clinical groups SDs for the various domains are nearly twice those of the non-clinical group. This
is unusual as lower mean scores typically shrink variability. Figures 15 and 16 illustrate the mean
differences amongst the age subgroups for the clinical and non-clinical samples.
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Table 9
Means and Standard Deviations (in parentheses) for Clinical and Non-Clinical Domain Scores
Domain
N
Clinical Group
n
Non-Clinical Group
Cognitive

50

70.72
(38.60)

80

98.98
(14.58)

Fine Motor

50

72.10
(38.63)

80

100.81
(13.30)

Visual Motor

50

62.6
(33.90)

80

100.40
(12.73)

Speed

50

84.42
(34.00)

80

99.73
(15.54)

Memory

50

65.00
(37.35)

80

99.80
(13.66)

Receptive
Language

50

65.48
(40.52)

80

97.99
(14.91)

Gross
Motor

50

74.48
(20.07)

80

100.02
(13.19)

Expressive
Language

41

59.76
(25.94)

76

102.04
(16.36)

Overall
Language

42

64.00
(26.02)

78

100.63
(15.92)

SocialEmotional

41

74.10
(22.80)

60

97.20
(12.60)

SelfHelp/Adaptive

42

79.50
(23.37)

62

98.53
(16.10)

110
100
90
80
70
60
50
40

30

Self-Help

Soc-Emot

Overall Lang

Exp. Lang

Gross Motor

Receptive Language

Memory

Speed

Visual Motor

Fine Motor

AD
Cognitive

Mean Standard Scores
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Figure 3. Domain standard score means scores for the Autism (AD) and non-clinical groups.

Figure 4. Distributions of the M-P-R Cognitive domain standard scores for the AD (n = 50) and
Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.

Determining the Clinical Utility of M-P-R Scales

31

Figure 5. Distributions of the M-P-R Fine Motor domain standard scores for the AD (n = 50)
and Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.

Figure 6. Distributions of the M-P-R Visual-Motor domain standard scores for the AD (n = 50)
and Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.
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Figure 7. Distributions of the M-P-R Speed domain standard scores for the AD (n = 50) and
Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.

Figure 8. Distributions of the M-P-R Memory domain standard scores for the AD (n = 50) and
Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.
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Figure 9. Distributions of the M-P-R Receptive Language domain standard scores for the AD (n
= 50) and Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.

Figure 10. Distributions of the M-P-R Gross Motor domain standard scores for the AD (n = 50)
and Non-Clinical Groups (n = 80). The Autism subgroup distribution is on the left.
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Figure 11. Distributions of the M-P-R Expressive Language domain standard scores for the AD
(n = 41) and Non-Clinical Groups (n = 76). The Autism subgroup distribution is on the left.

Figure 12. Distributions of the M-P-R Total Language domain standard scores for the AD (n =
42) and Non-Clinical Groups (n = 78). The Autism subgroup distribution is on the left.
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Figure 13. Distributions of the M-P-R Social-Emotional domain standard scores for the AD (n =
41) and Non-Clinical Groups (n = 60). The Autism subgroup distribution is on the left.

Figure 14. Distributions of the M-P-R Self-Help/Adaptive Behavior domain standard scores for
the AD (n = 42) and Non-Clinical Groups (n = 62). The Autism subgroup distribution is on the
left.
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Table 10
Means and Standard Deviations for Clinical and Non-Clinical Domain Scores by Age
Clinical Group

Non-clinical Group

Domain

Age
< 61 months
n = 23

Age
> 61 months
n = 27

Age
< 61 months
n = 39

Age
> 61 months
n = 41

Developmental Index

60.57
(35.69)

63.22
(39.59)

97.41
(14.83)

101.71
(13.85)

Cognitive

63.26
(33.62)

77.07
(42.02)

96.59
(15.24)

101.24
(13.73)

Fine Motor

73.30
(37.16)

71.07
(35.05)

99.08
(12.75)

102.46
(13.7)

Visual Motor

62.70
(33.27)

62.52
(35.06)

99.44
(10.58)

101.32
(14.55)

Speed

84.96
(34.49)

83.96
(34.19)

97.21
(15.51)

102.12
(15.38)

Memory

61.74
(34.18)

67.74
(40.30)

99.54
(14.29)

100.02
(13.20)

Receptive Language

62.87
(39.04)

67.70
(42.34)

97.23
(14.00)

98.71
(15.85)

Gross Motor

78.30
(16.33)

71.22
(22.74)

100.21
(12.30)

99.85
(14.13)

A 2 (clinical vs. non-clinical) x 2 (younger vs. older age groups) x 7 (domains)
MANOVA was calculated. Box’s Test revealed that equal variances should not be assumed (F
(84, 24439) = 2.18, p < .001); therefore, Pillai’s Trace was used as the indicator of significance.
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The main effects of group (F(7, 120) = 26.12, p < .001, η2= .604) and age category (F(7, 120) =
4.65, p <.001, η2= .213) were both found significant. The non-clinical older and younger groups

Table 11
Means and Standard Deviations for Clinical and
Non-Clinical Supplemental Domain Scores by Age
Clinical Group

Non-clinical Group

Age
< 61 months

Age
> 61 months

Expressive Language

64.78
(26.36)
(n =18)

55.83
(25.49)
(n = 23)

99.92
(16.72)
(n = 39)

104.27
(15.89)
(n = 37)

Language Total

61.81
(31.36)
(n = 16)

65.27
(22.70)
(n = 26)

98.69
(16.66)
(n = 39)

102.56
(15.11)
(n = 39)

Social-Emotional

80.12
(18.87)
(n = 17)

69.83
(24.70)
(n = 24)

94.86
(11.90)
(n = 29)

99.39
(13.02)
(n = 31)

Self-Help

77.00
(19.98)
(n = 17)

81.20
(25.67)
(n = 25)

97.62
(15.23)
(n = 29)

99.33
(17.02)
(n = 33)

Domain

Age
Age
< 61 months > 61 months

consistently scored higher across all the domains. A significant interaction between group and
age was also obtained, F(7, 120) = 2.13, p = .05, η2= .111). Univariate ANOVA results indicated
that the non-clinical group significantly differed for seven M-P-R domains: Cognitive (F(1, 126)
= 36.62, p <.001, η2= .225); Fine Motor (F(1, 126) = 41.47, p <.001, η2= .248); Receptive
Language (F(1, 126) = 42.23, p <.001, η2= .251); Memory (F(1, 126) = 57.36, p <.001, η2=
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.313); Speed (F(1, 126) = 11.87, p =.001, η2= .086); Visual Motor (F(1, 126) = 79.78, p <.001,

η2= .388); Gross Motor (F(1, 126) = 74.57, p <.001, η2= .372). The younger age group was
found to be performing significantly lower for the Cognitive domain (F(1, 126) = 3.78, p =.05,

η2= .029. Age group was not found to be significant for Fine Motor (F(1, 126) = .02, p =.90,

Standard Scores

η2=
90	
  
85	
  
80	
  
75	
  
70	
  
65	
  
60	
  
55	
  
50	
  

AD	
  Older	
  
AD	
  Younger	
  

	
  

Standard Scores

Figure 15. Mean score distribution of the M-P-R domains for AD age groups.
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Figure 16. Mean scores across M-P-R supplemental domains for Non-Clinical age groups.
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.000); Receptive Language (F(1, 126) = .39, p =.53, η2= .003); Speed (F(1, 126) = .20, p =.66,

η2= .002); Visual Motor (F(1, 126) = .04, p =.84, η2= .000); or Gross Motor (F(1, 126) = 1.61, p
=.21, η2= .013).
The supplemental domains were next evaluated using a 2 (clinical vs. non-clinical) x 2
(younger vs. older age groups) x 4 (domains) MANOVA. Box’s Test revealed that equal
variances should not be assumed (F (30, 6655.14) = 6.91, p < .001); therefore, Pillai’s Trace was
used as the indicator of significance. The main effect of group (F(4, 78) = 27.13, p < .001, η2=
.58) was significant; the non-clinical group consistently scored higher across all the domains.
Age category (F(4, 78) = .95, p = .44, η2= .05) was not found to be significant. A significant
interaction between group and age was found (F(4, 78) = 3.31, p = .02, η2= .15) and likely due
to the higher Social-Emotional domain score for the younger clinical group. Univariate ANOVA
results indicated that group significantly differed for the four supplemental M-P-R domains:
Expressive Language (F(1, 81) = 77.17, p <.001, η2= .488); Language Total (F(1, 81) = 49.97, p
<.001, η2= .382); Social-Emotional (F(1, 81) = 29.43, p <.001, η2= .267); and Self-Help (F(1,
81) = 12.13, p <.001, η2= .130). Age group was not found to be significant with Expressive
Language (F(1, 81) = .01, p =.94, η2= .00); Language Total (F(1, 81) = .55, p =.46, η2= .007);
Social-Emotional (F(1, 81) = 1.52, p = .22, η2= .018); and Self-Help (F(1, 81) = .001, p =.98,

η2= .00). Figures 17 and 18 illustrate the mean difference by age group for the Non-Clinical
sample.
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The M-P-R performance by the clinical group was then compared to performance of
other clinical groups whose test results were included in the M-P-R Manual, including a small
sample of 14 children diagnosed on the autism spectrum (i.e., A D, Asperger’s Disorder, and
PDD). Table 12 identifies these clinical groups and Table 13 provides their M-P-R means and
SDs across the domains. The clinical and non-clinical samples from this study have also been
included in Table 13. Data available were limited to means and SDs for each of the clinical
groups found in the Manual, therefore statistical analyses were not possible. Nevertheless, some
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Figure 17. Mean scores across M-P-R domains for non-clinical age groups.
	
  

Determining the Clinical Utility of M-P-R Scales

41

Standard Scores

110	
  
105	
  
100	
  
95	
  
90	
  
85	
  
80	
  

Non-‐Clinical	
  Older	
  
Non-‐Clinical	
  Younger	
  

Figure 18. Mean scores across M-P-R domains for non-clinical age groups.
interesting comparisons are warranted; Figure 19 illustrates the patterns of the scores presented
in Table 13. First, the Autism Spectrum group obtained noticeably lower scores in each domain
with the exception of the Memory and the Gross Motor domain. As anticipated, the non-clinical
group’s mean scores across the domains are close to average while the Cognitive Delay,
Speech/Language Impaired, Motor Delay groups all obtained below mean scores within each
domain (with the exception of the Speech/Language Impaired domain score for Gross Motor).
Children within the Premature Infant group achieved domain scores near average. Children
within the Deaf group also achieved scores close to average across all domains with the
exception of Receptive Language and the Gross Motor; these scores fell nearly two and one
standard deviations below the non-clinical group, respectively. Further, the means reported in the
M-P-R Manual for the Speed domain appear to be a relative strength (i.e., the highest score,
albeit well below the non-clinical score) for the Cognitive Delay, Motor Delay, ASD and this
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study’s clinical group. This finding may suggest that the items within the Speed domain are not
as sensitive to fine motor delays in young children.
Also, there appears to be a fair amount of overlap across the clinical groups. This study’s
clinical group showed the most overlap with Speech/Language Impaired, Deaf, and Motor Delay
groups in the Receptive Language domain. The overlapping scores with other clinical subgroups
suggest that the M-P-R, although sensitive to significant developmental delay, does not seem to
differentiate between other early disabling conditions; therefore, it should not be used to
establish an ASD diagnosis. Even comparing two ASD subgroups, there was noticeable absence
of overlap in several domains. Therefore, there seems to be little basis to assert that there is an
“ASD pattern” yielded by the M-P-R.
Table 12
Clinical Groups as Defined in the M-P-R Manual
Clinical Condition

Definition

Median Age
(months)
56

Cognitive Delay (n= 32)

Mild, Moderate or Severe Mental
Retardation

Premature Infants (n = 39)

Children born 37 weeks or less gestational
age as reported by parents

11

Severe Speech/Language
Delay (n = 43)

Children with documented delays in either
speech or language development

47

Deafness or Severe Hard-ofHearing Conditions (n = 18)

Children documented as deaf or severe
hearing difficulties

49

Severe Motor Delay (n = 15)

Children with documented motor delays or
deviations (Cerebral Palsy, etc)

50

Autistic Spectrum (n = 14)

Children with documented diagnosis of
autism or autism spectrum disorder.
Note. M-P-R = Merrill-Palmer-Revised.

53

Mean Standard Scores
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Figure 19. Merrill Palmer-Revised standard score means across domains for various clinical
groups described in the M-P-R test Manual, along with the current study’s AD and non-clinical
groups. CogDelay = cognitive delay; Lang = language; Impair = impairment; ASD = Asperger’s
Disorder; Non-Clin = non clinical.
Table 13
Means and Standard Deviations (in parentheses) of the M-P-R Standard Scores for Clinical
Groups Reported in the M-P-R Manual, in Addition to This Study’s Clinical and Non-Clinical
Groups
M-P-R
Domain
Clinical
Groups

Cog.

Fine
Motor

Recep.
Lang

Memory

Speed

Visual
Motor

Gross
Motor

Cognitive
Delay
(n = 25)

49.6
(26.4)

47.0
(26.5)

*

53.6
(26.0)

60.3
(24.1)

48.9
(22.7)

54.3
(26.3)

Premature
Infants
(n = 36)

94.2
(22.3)

90.8
(19.6)

*

*

*

92.1
(18.0)

90.9
(24.0)

Speech/
Lang.
Impaired
(n = 42)

85.8
(22.7)

87.2
(21.5)

76.4
(15.2)

87.3
(21.1)

86.5
(19.0)

88.1
(20.1)

90.6
(22.0)
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(n = 16)

92.5
(21.9)

94.4
(21.0)

72.8
(19.5)

95.4
(20.1)

93.4
(18.9)

95.5
(21.6)

83.9
(25.4)

Motor
Delay
(n =13)

76.5
(35.8)

72.3
(33.9)

73.4
(25.4)

73.9
(31.0)

80.6
(38.8)

74.3
(33.3)

70.9
(31.3)

Autism
Spectrum
(n = 14)

58.7
(30.7)

58.9
(26.3)

54.2
(15.6)

68.3
(22.9)

69.4
(23.2)

57.1
(23.2)

75.5
(15.0)

Clinical
Group
(n = 50)

70.7
(38.6)

72.1
(35.7)

65.5
(40.5)

65.0
(37.4)

84.4
(34.0)

62.6
(33.9)

74.58
(20.0)

NonClinical
Group
(n = 80)

98.9
(14.6)

100.8
(13.3)

98.0
(14.9)

99.8
(13.7)

99.7
(15.5)

100.4
(12.7)

100.0
(13.2)
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Note. M-P-R = Merrill-Palmer-Revised; Cog. = Cognitive; Recep. = Receptive; * = not reported.
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Chapter 4
Discussion

This study assessed important aspects related to the clinical utility of the M-P-R in the
assessment of children diagnosed with AD. The Developmental Index scores for the AD sample
gathered for this study ranged from 10 to 115, indicating that this clinical group consists of
children with a broad range of functioning levels, which is common with his population. Other
studies have reported below mean standard scores with large standard deviations. For example,
Coolican, Bryson, and Zwaigenbaum, 2008 reported an AD sample with a SB-5 mean Full Scale
IQ and SD of 67.75 and 21.02, respectively. Tsatsanis et al. (2003) reported an AD sample with a
Leiter-R mean Full Scale IQ of 68.8 and SD of 22.3. Therefore, while large standard deviations
for samples of autistic children are typical, the standard deviation obtained in the present study is
almost 50% larger than the two studies just cited. In part, the greater variability found in this
study’s autism group, is likely attributable to the large number of participants (52%) who
obtained a Developmental Index score below 70. In addition, it is well known that children with
AD struggle with imitation tasks, using gestures, and utilizing functional language. Several M-PR tasks may have been too difficult as eleven participants obtained a Developmental Index score
of < 20. A similar experience was reported by Akshoomoff (2006) when several ASD
participants obtained T – scores < 20 on the Mullen Scales of Early Learning (Mullen, 1995).
However, in his particular study the children were much younger (mean age = 29.9 months SD =
7.6). The children who obtained very low scores in the present study ranged in age from 40 – 70

Determining the Clinical Utility of M-P-R Scales

46

months. One reason could be that the combination of severe autism symptoms, poor attention,
and item difficulty contributed to the extremely low scores. Another reason, and as mentioned
previously, research has found that intellectual disability is likely to be comorbid with AD
(Edelson, 2006; Fombonne, 2005; Hartley & Sikora, 2010). The high variability, and those with
severe cognitive impairment in the present study, raises questions whether these participants may
have been improperly diagnosed or if other co-morbidities were included (i.e., Fragile X).
In an attempt to reduce the high variability, and possible floor effects, 11 participants
who received a Developmental Index score < 20 were removed and the resultant subsample’s MP-R scores along with the original sample’s scores are shown in Table 14. This subsample’s data
have been added to Figure 19, and can be viewed in Figure 20.

Table 14
Means and Standard Deviations (in parentheses) of the M-P-R Standard Scores for the AD
Group obtaining a Developmental Standard Score > 20, in Addition to This Study’s Clinical and
Non-Clinical Group
M-P-R
Domain
Groups
Cog.
Fine
Recep.
Memory
Speed
Visual
Gross
Motor
Lang
Motor
Motor
Revised
Clinical
Group
(n = 39)

85.56
(29.54)

87.97
(21.30)

81.13
(31.22)

79.62
(28.19)

99.26
(19.25)

76.67
(23.53)

81.26
(14.71)

Clinical
Group
(n = 50)

70.7
(38.6)

72.1
(35.7)

65.5
(40.5)

65.0
(37.4)

84.4
(34.0)

62.6
(33.9)

74.58
(20.0)

Non98.9
100.8
98.0
99.8
99.7
100.4
100.0
Clinical
(14.6)
(13.3)
(14.9)
(13.7)
(15.5)
(12.7)
(13.2)
Group
(n = 80)
Note. M-P-R = Merrill-Palmer-Revised; Cog. = Cognitive; Recep. Lang = Receptive Language.
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Figure 20. Merrill Palmer-Revised standard score means across domains for various clinical
groups described in the M-P-R test Manual, along with the current study’s revised AD group.
CogDelay = cognitive delay; Lang = language; Impair = impairment; ASD = Asperger’s
Disorder; AD = Autistic Disorder; Non-Clin = non clinical.
As expected, the results of the updated AD group show increased domain standard
scores, but of interest, the large standard deviations remain. The main reason to eliminate
participants with very low scores was to examine whether an AD profile of M-P-R scores might
emerge. Figure 20 shows the revised subsample compared to the original clinical sample and a
several other clinical groups. Clearly, the AD revised sample’s scores are no longer overlapping
with the Cognitive Delay and ASD groups. However, the revised group scores overlap with other
clinical groups, such as those with speech/language delays, children who are deaf, and those who
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were born prematurely. Unfortunately, the revised domain scores still do not suggest a unique MP-R profile exists for children with AD. In particular, it is curious why children with AD disorder
do not seem to have M-P-R receptive language scores suggestive of significant language
impairment, a central diagnostic characteristic of autism. As seen in the original AD group, the
Speed domain remained the domain yielding the highest score, which was well within the
average range. Therefore, excluding the lowest scoring children with AD did not help create a
more diagnostically useful AD profile, reinforcing the finding that the M- P- R should not be
used by itself to make the diagnosis of AD disorder.
In examining psychometric properties of the M-P-R, the internal consistency of its
Cognitive Battery (Cognitive, Fine Motor, Receptive Language, Memory, Speed, and Visual
Motor) was found to be strong. The alpha values for the autistic sample exceeded the values
reported in the Manual for the standardization sample (Roid & Sampers, 2004). The high internal
consistency indicates that the items within each domain are homogeneous and useful in skill
assessment. While data are yet needed to establish test-retest reliability for an autistic sample,
this study provides preliminary support for sound reliability using one reliability index (internal
consistency). Other than the standardization data found in the M-P-R Manual, comparable
research regarding internal consistency was not found.
In terms of the validity, a surprising result was observed when the M-P-R Cognitive
Battery domains for the AD group were correlated. As shown in Table 6, all of the domain
correlations were greater than .85 (.86-.98), suggesting that a much stronger inter-relationship
between domains exists for children with AD compared to the non-clinical sample. Only one
correlation was found to be greater than .85 for the non-clinical group, namely, the relationship
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of the Cognitive domain with the Developmental Index (r = .96), which is expected as the
Cognitive domain contributes to the Developmental Index score. Apart from the Cognitive
domain correlation with the Developmental Index, the greatest correlation using the non-clinical
sample was observed between Cognitive and Memory domains (r = .83) and the lowest between
Speed and Visual Motor (r = .34). For the most part, when looking at the non-clinical group, the
low to moderate inter-domain correlations appear to support the M-P-R’s construct validity. Yet,
when used with an AD population, the instrument’s construct validity appears compromised. The
AD group was found to have a .98 correlation between Fine Motor and Visual-Motor compared
to the .80 correlation with the non-clinical group, strongly suggesting each scale is measuring the
same thing, and therefore there is little psychometric justification for including two highly
overlapping domains. The exception to this considerable overlap is seen for the Gross Motor
whose correlations were also found to be higher for the AD group when compared to the nonclinical group (r = .66 - .70 vs. .24 - .41), but not as suggestive of the redundancy connoted in the
other domain correlations. Similar findings were found in a study by Dickerson-Mays & Calhoun
(2003) in which correlations of subtests of the SB-IV and Indexes of the WISC-III were higher
for the autism group in comparison to the standardization sample. Interestingly, when interdomain correlations were made between the supplemental scales the high values disappeared
with the exception of the Self-Help and Social-Emotional domains (.83). This suggests that the
supplemental language scales, when used with an AD population, appear to question the validity
of parent report. Referring back to Table 7 it is apparent that the correlations are much lower
when comparing the correlations of the Non- Clinical group. From a clinical standpoint it would
appear best to not use the supplemental parent scales when working with an AD population.

Determining the Clinical Utility of M-P-R Scales

50

When the mean standard scores obtained by the AD and non-clinical groups were
compared, as anticipated, the domain scores of the AD group were found to be consistently
lower (approximately 2.0 to 2.5 standard deviations lower), with the exception of Speed (which
was about one standard deviation below). These results are similar to a study by Coolican,
Bryson, and Zwaigenbaum (2008) in which 32 children with a mean age of 7 years, 5 months
(SD = 2.71) diagnosed with AD completed the SB-5 and obtained mean Index scores falling
approximately two standard deviations below average. Additionally, Tsatsanis et. al., (2003)
administered the Leiter-R to 22 children with a mean age of 9.13 years (SD = 3.47) diagnosed
with AD who obtained a mean Full Scale IQ score of 68.8. The AD group in this study obtained
scores well below the mean when compared to a non-clinical group but similar to other studies
assessing children with AD. This suggests that the M-P-R is sensitive in indentifying children
with developmental delay.
The AD sample performed as expected (lower) in all of the domains when compared to a
non-clinical sample, with the exception of Speed. There are differing views regarding the speed
of processing abilities within an autistic population. Scheuffgen, Happe, Anderson, & Frith
(2000) administered an inspection time computer task and found lower processing speed
(equivalent to the non-clinical sample) in children with an ASD despite their low average IQ.
Additionally, Akshoomoff, (2006) found that participants with ASD performed relatively better
on the Fine Motor scale of the Mullen Scales of Early Learning (Mullen, 1995). Alternatively,
Calhoun & Dickerson-Mayes (2005) and Oliveras-Rentas, Kenworthy, Roberson, Martin, &
Wallace (2012) found processing speed (as assessed by the WISC-III and WISC-IV) to be a
relative weakness compared to a non-clinical sample. The participants of the current study
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obtained higher than expected processing speed scores, but not as high as the participants in the
Scheuffgen et al. (2000) study, who obtained average scores; the reader will remember that the
AD group of this study obtained scores falling one standard deviation below average. While
perhaps at a different degree of magnitude, nonetheless, the processing speed results of this study
seem to align more as a strength rather than a weakness.
Comparisons were made across several clinical groups identified in the M-P-R Manual.
Several groups obtained somewhat similar M-P-R domain patterns. The greatest group
similarities seemed to be between the AD clinical group and the Motor Delay group. The Speed
Domain mean score appears to be a relative strength for both groups, which may suggest that the
Speed Domain may be less impacted by delays as the other domains. The M-P-R Speed domain
is calculated based upon quick performance on the Visual-Motor domain tasks. Examples of
these tasks include speed in stacking rings, placing six round or square pegs in the appropriate
holes, assembling two, three, and four piece puzzles, and placing form board shapes (e.g., circle
and square) in their correct locations. If the tasks are completed faster than a specified time, a
bonus point is awarded. One would expect children with motor delays to demonstrate difficulty
completing fine motor tasks efficiently. Yet results indicate that the Motor Delay group obtained
the highest score in the Speed Domain. The AD clinical group also performed the highest within
this domain. Because the Speed domain appears to generate performance anomalies for the AD
and Motor Delay groups, it would appear that the Speed domain may be a poor measure of
processing speed abilities, at least with these particular groups, or that the tasks within this
domain measure something quite different than is normally associated with performance
efficiency of sensory-motor skills.
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Despite its sensitivity to identify delays, there is less evidence that the M-P-R provides
good diagnostic specificity between clinical subgroups. There did not seem to be an autistic MP-R profile that was distinctive from other clinical groups, although there are some markers that
deserve more attention in future studies using larger samples. The Cognitive, Fine Motor,
Receptive Language, and Memory domains seem especially low for children with AD and ASD,
as is shown in Figure 12. Clinicians may be more inclined to consider an ASD or intellectual
disability diagnosis rather than the other clinical groups identified based upon relatively lower
scores in these domains. However, given the M-P-R performance overlap among several clinical
groups, it is not appropriate to use M-P-R results in making a differential diagnosis of these other
conditions.
Implications
The need to accurately assess a child suspected of AD is vital to ensure appropriate
treatment plans are employed. This study evaluated aspects of the psychometric properties of the
M-P-R in the evaluation of children with AD. One measure of reliability (internal consistency)
was found to be good. This particular population is recognized as being difficult to assess and the
M-P-R was found to have weaknesses in regards to its validity with this sample of AD
participants. The inter-domain correlations of the Cognitive Battery indicated that the items are
highly correlated and do not appear to assess the individualized skill areas as found with the nonclinical standardization sample. This suggests that although the M-P-R is capable of identifying
global delays, obtaining information regarding specific skills measured is less clear when
working with an AD population. However, when working with children who are unable to basal
on other measures of cognition (i.e., SB-5, WISC-IV, etc) the M-P-R should be considered
useful in the identification of developmental delays.
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The M-P-R is not recommended to be used as an AD diagnostic tool; however, if the
identification of a child suspected of an ASD is in question, and using the values in Table 13
along with a “rule-of-thumb” that if all M-P-R scores are below 75 (with Speed domain removed
from the comparisons) yet higher than 55, it is reasonable to consider an ASD diagnosis.
Unfortunately, since individual scores from the children in the various diagnostic subgroups are
not available, the utility of this diagnostic guideline cannot be determined, but could be a focus
of future research. And given the large SDs found in the AD group, most any diagnostic
guideline related to M-P-R domains would not likely prove useful when working with an
individual child. Overall, the M-P-R does not appear to be a valid tool for the diagnostic
assessment of children with an AD diagnosis. The domains comprising the Cognitive Battery are
highly inter-related and the domain scores tend to be similar to those diagnosed with disabilities
other than AD. Additionally, the parent report measures showed very low correlations and
suggest that the supplemental measures do not aid in the diagnostic process. Therefore, while it
seems sensitive to identifying dysfunction, it is not specific enough to indicate if the dysfunction
may be AD.
Limitations and Future Directions
There are several limitations to this study. Autism severity was not assessed. The ADOS
algorithm scores obtained from the hospital recruited children were archival data but the raw
scores for each ADOS domain were not available. As such, Modules 1-3 were not comparable.
Gotham, Pickles & Lord (2009) have developed a system to standardize ADOS scores for the
purpose of assessing severity. This information would have been useful to use in order to
compare ADOS scores with the results of the M-P-R, as the ADOS is considered the “gold
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standard” in autism diagnosis. It would be interesting to see which domains correlate the most
closely with the various ADOS scores.
The present study was unable to perform a discriminate function analysis using the AD
clinical group and the previously identified clinical groups found in the M-P-R Manual due to a
limitation in available data from the other clinical groups, as well as rather small sample sizes.
As a result, observations were made based upon superficial comparisons of group means and
standard deviations. Future collaborative studies across institutions may provide access to larger
and diagnostically diverse data sets.
Also, a longitudinal investigation using the M-P-R would have value. The mean age of
participants in this study was 5.0 years, and it would be useful to identify the utility of the M-P-R
in identifying delays of children suspected of ASD at a younger age as the M-P-R has been
developed for the use in children as young as one month. A longitudinal study of infants
identified with delays may be useful to observe the developmental progression and determine if
there are patterns seen early on that later would help diagnostically differentiate among autism,
intellectual disability, speech and language delay and other subgroups demonstrating
developmental abnormalities.
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DSM-IV-TR Diagnostic Criteria for Autism: (where appropriate rate each question: 1)
behavior present and seen regularly in different situations and environments; 2) behavior
sometimes seen or seen only in a specific situation or environment; or 3) behavior not seen or
not yet developed)
Qualitative impairment in social interaction, as manifested by two of the following:
Y N
Marked impairment in the use of multiple nonverbal behaviors such as eye-to-eye
gaze, facial expression, body postures, and gestures to regulate social interaction.
⎯ in general, will look you/others in the eye, e.g., when he/she wants
something
⎯ will nod his/her head for “yes,” shake his/her head for “no,” wave “bye-bye”
at appropriate times, point to indicate his/her wants, use other gestures
⎯ does he/she look at you when you start talking to him/her or doing things
with him/her
⎯ will he/she turn his/her head to look at you when you call his/her name
⎯ will he/she look where you point when you point to show him/her a toy or a
picture in a book
⎯ does he/she point to a toy or object to show you he/she is interested in it
⎯ does he/she smile, frown, raise his/her eyebrows. . . show a variety of facial
expressions (can you tell how he/she’s feeling or what he/she’s thinking by
his/her facial expressions)
⎯ does he/she gesture with his/her hands when he/she’s talking
Y N
Failure to develop peer relationships appropriate to developmental level
⎯ is he/she interested in other children
⎯ does he/she talk to or try to join other children in their play (e.g., at the park,
school or daycare, how does he/she join another child or a group; for example,
start playing next to them)
⎯ how does he/she respond if other children talk to or try to play with him/her
⎯ how many friends does he/she have (children he/she plays with regularly)
⎯ does he/she invite friends over to play and is he/she invited to play at other
children’s houses (ask about play “dates” set up by parent)
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⎯ what do they do when they play together, e.g., parallel play only, chase, video
games, make believe play
⎯ are his/her relationships based primarily on his/her special interests
⎯ does he/she have trouble participating in groups, following cooperative rules of
games
Y N
A lack of spontaneous seeking to share enjoyment, interests, or achievements with
other people (e.g., by a lack of showing, bringing, or pointing out objects of interest)
⎯ does he/she try to involve you in his/her play, in his/her favorite activities or
does he/she prefer to play by himself/herself
⎯ how does he/she try to engage you
⎯ does he/she bring a toy or book to show you what he/she is doing
⎯ how does he/she respond to praise
⎯ does he/she offer to share things (toys or food) with you; and will he/she offer to
share things with other children
⎯ at different times, does he/she frown and pout, act embarrassed, look surprised
or look happy and excited (show a range of emotions)
⎯ how does he/she share his/her feelings with you, e.g., his/her excitement after
drawing a picture that he/she really likes, and how does he/she respond to praise
⎯ does he/she like to be held or cuddled, does he/she give hugs and kisses (does
he/she imitate you or does he/she spontaneously give a hug)
Y N
Lack of social or emotional reciprocity
will he/she play ball by rolling or throwing it back and forth
does he/she play other games that require turn taking
is he/she interested in what game you want to play or what you want to do
does he/she recognize how you are feeling, e.g., when you’re happy, angry
sad or ill, will he/she try to comfort you
⎯ does he/she notice when others are upset or hurt
⎯ does he/she realize certain things he/she does bother others
⎯
⎯
⎯
⎯
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Qualitative impairments in communication as manifested by at least one of the following:
Y N
Delay in, or total lack of, the development of spoken language (not accompanied
by an attempt to compensate through alternative modes of communication such as gesture
or mime)
⎯ how many words and gestures does he/she use
⎯ does he/she use words or gestures to indicate his/her wants (e.g., does he/she
point to indicate wants)
⎯ how does he/she usually let you know what he/she wants or when he/she needs
something
Y N
In individuals with adequate speech, marked impairment in the ability to initiate
or sustain conversation with others
⎯ can you have a conversation with him/her. For example, if you make a comment
but don’t ask a question, will he/she say something in response
⎯ will he/she start a conversation with you just to talk or chat, not to ask for
something
⎯ can he/she take turns in a conversation or is it usually one-sided, e.g., does
he/she always want to talk about his/her favorite subject
⎯ does he/she notice when you’ve lost interest in talking or does he/she talk on
and on
⎯ does he/she interpret what you say literally or concretely, e.g., “what’s up”
(what are you doing) or “you must have springs in your shoes” (to jump that
high) or “hop to it” (hurry)
Y N
stereotyped and repetitive use of language or idiosyncratic language
what word or name does he/she use to refer to himself/herself
does he/she sometimes mix up pronouns, e.g., you for I, he or she for I
does he/she say what you say right after (immediate echolalia)
does he/she repeat the same phrase over and over
does he/she use pat or set phrases, e.g., things you may have said or that
he/she heard someone else say, such as from a TV show or movie (delayed
echolalia)
⎯ talk to himself during play, or make nonsense noises or words to
himself/herself during play (words that he/she made up)
⎯ does he/she seem to talk too loudly or too softly
⎯
⎯
⎯
⎯
⎯
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⎯ does he/she use the same tone of voice each time or have a sing-song pattern
to his/her/her voice?
Y N
lack of varied, spontaneous make-believe play or social imitative play appropriate to
developmental level
⎯ will he/she play games such as pat-a-cake or peek-a-boo; make hand gestures to
familiar songs such as “itsy-bitsy-spider”; fill in a word in a familiar song like
“wheels on the bus”
⎯ does he/she like to “pretend” or “make-believe” when playing. For example, will
he/she pretend to talk on a toy phone or pretend to feed or take care of a doll or
stuffed animal? Will he/she dress-up and “make believe” he/she is someone else
⎯ does he/she pretend a toy is something else, e.g., a toy banana is a phone or a block is
a sandwich
Restrictive repetitive and stereotyped patterns of behavior, interests, and activities as
manifested by at least one of the following:
Y N
Encompassing preoccupation with one or more stereotyped and restricted
patterns of interest that is abnormal either in intensity or focus
⎯ what are his/her favorite toys and activities
⎯ does he/she always play with toys in the same way, e.g., by lining up toy cars or
sorting toys by color
⎯ does he/she have a special (all encompassing) interest in one toy, activity or
subject (e.g., trains or flags) or an interest in unusual objects or topics (e.g.,
sprinkler systems, astrophysics)
⎯ how does he/she react if you try to change a favorite activity or topic of
conversation
⎯ does he/she have an unusually good memory for the details of special interests,
family activities or vacations
Y N
Apparently inflexible adherence to specific, nonfunctional routines or rituals
⎯ does he/she have rigid rituals or routines. For example, are there things
he/she
has to do in a particular way or in an exact order every time at mealtime, bedtime
or during play
⎯ how does he/she react if his/her routine is interrupted or he/she can’t complete it
(e.g., a toy is broken or missing, he/she has to sleep at a motel when on vacation,
you drive a different way home)
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⎯ how does he/she react to changes in his/her schedule (e.g., school assembly
canceled) or changes in his/her environment, (e.g., how the furniture is arranged
at home or classroom, where he/she sits at the dinner table)
⎯ does he/she repeat certain activities over and over, for example: with objects
(dropping or rolling; always carrying a specific object); cleaning (washing) hands;
use of toilet paper; checking) appliances off, doors closed); counting (toys,
money); or ordering (toys, clothes, towels in bathroom). Do these activities
interfere with day-to-day function
Y N
Stereotyped and repetitive motor mannerisms (e.g., hand and finger flapping or
twisting, or complex whole-body movements)
⎯ does he/she have any mannerisms or odd ways of moving his/her hands or
his/her body that look the same each time, e.g., flapping hands when excited,
walking on his/her toes, flicking his/her fingers, spinning or rocking his/her
body, running in a circle
Y N
Persistent preoccupation with parts of objects
⎯ does he/she mostly play with objects that light up or make sounds, objects that
move or spin, e.g., wheels, fans, running water
⎯ does he/she pay attention only to part of the toy, e.g., spinning the wheels of the
car rather than driving it around on a “make-believe” road,
⎯ does he/she use toys or objects in unusual ways, e.g., repeatedly opens and
closes doors of toy cars, touches most toys to his/her lips/mouths toys, holds
toys very close to his/her eyes or looks out of the “side” of his/her eyes at toys
⎯ does he/she have an attachment to unusual objects, e.g., string
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Oregon Health & Science University
Consent Form

eIRB#:

4031

Protocol Approval Date: 3/18/2009
OREGON HEALTH & SCIENCE UNIVERSITY

Consent Form
TITLE: Possible Role of Cholesterol Metabolism in the Etiology of Autism, and Correlates with
Neurocognitive/Neurobehavioral Phenotype
PRINCIPAL INVESTIGATOR:

Michael Harris, Ph.D.

(503) 494-8942

CO-INVESTIGATORS:

Trevor A. Hall, Psy.D.

(503) 494-0333

Robert Steiner, M.D.

(503) 494-2783

Cheryl Maslen, Ph.D.

(503) 494-2011

Michael Kruer, M.D.

(503) 494-8211

Meaghan Peters

(503) 494-0333

Diomaris Jurecska

(503) 494-0333

Karen Grant

(503) 418-1832

STUDY STAFF:

SPONSOR: Northwest Health Foundation
PURPOSE: You and your child are being asked to participate in this study because your child has been
diagnosed with an autism spectrum disorder. About 80 participants will participate over the next two
years. The purpose of this research study is to gather information about children with autism spectrum
disorder (ASD). We aim to understand the neuropsychological profiles that exist for people with ASD
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and use this data to improve the treatment, care, and quality of life for individuals with ASD and their
families.
We also think that genes important in making cholesterol may impact autism. If a gene or genes that
effect autism can be found, the diagnosis and treatment of autism may be improved. Genes are the units of
DNA—the chemical structure carrying your genetic information—that determine many human
characteristics such as the color of your eyes, your height, and whether you are male or female. As part of
this study, we will ask your child to provide blood samples for genetic testing. If your child has had blood
drawn in another autism-related study here at OHSU he/she will not have another draw for this study. The
blood samples will be analyzed in the laboratory to determine whether there are differences in the
cholesterol-making genes of people with autism. If you agree, your child’s blood samples will be stored
indefinitely and used for future research studies that may include genetic research.
PROCEDURES:
Your participation will last up to 3 months. During this time, some tests will be completed during inperson visits at the CDRC clinic. Questionnaires will be filled out by the parent or primary caregiver and
may be filled out away from the clinic. The number of in-clinic visits will be determined by the
parent/caregiver and investigator as needed to complete the testing in a 3-month time period. You will
receive a report on the testing.
If you agree to participate in this study, the initial study visits will be conducted to complete the eligibility
requirements using two diagnostic measures, ADI-R and the ADOS-G. If your child has been evaluated
through the CDRC Autism Program he/she will not need to repeat the ADOS-G or ADI-R.
1
2

The ADI-R is a parent interview that will ask for a thorough description of the child’s cognitive,
social, communicative, and behavioral development. The ADI-R takes 1 to 3 hours to complete
and will be done with the parent/caregiver in person at the clinic.
The ADOS-G is an assessment observing the child’s social and communicative abilities using
age-appropriate toys. The ADOS-G takes ½ hour to an hour to complete and must be completed
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with your child at the clinic.
The next study visit will be scheduled for you and your child to begin study testing. Multiple site visits
may be required and you and the research study staff will determine the schedule. There are a set number
of assessments that you will have to complete, some of which will be completed with your child while
others are interviews or questionnaires you will complete. All assessments with your child will be
completed at the clinic site. Some questionnaires will be completed during an interview while you will
complete others at home. Staff will be available to answer any questions you may have.
The assessments will include measures that will focus on your child’s development in the areas of:
1
2
3
4
5
6

Cognition
Adaptive skills
Speech and language
Motor skills
Behavior
Psycho-social development

Your first study site-visit with the investigator will be scheduled with the staff. The remaining parent
questionnaires will be provided to you at each site visit until all have been completed. The assessment
study visit will take 2 to 4 hours.
You will be asked to complete all testing within a 3 month time period.
Your second study site-visit will be an appointment for a blood draw (if feasible you will be offered a
blood draw during the first study visit). The blood draw will occur at the Oregon Clinical and

Translation Research Institute (OCTRI).
In the OCTRI a nurse or research assistant will draw about one tablespoon of blood from a vein in your
child’s arm. This should take less than five minutes. We will use your child’s blood to measure
cholesterol and related compounds and to analyze genes that are involved in making cholesterol. You
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will be allowed to stay with your child during the blood draw and your child will get a small toy for
helping with the study.
In addition to the above procedures, if you child has been evaluated through the OHSU Autism Program,
historical test results will be recorded from your child’s OHSU medical record and used in this study.
In the future, samples of your child’s blood may be given to researchers as part of the search for a genetic
cause of autism. You will be given a choice as to whether you want your child to participate in this part of
the study.
If you have any questions regarding this study now or in the future, contact Michael Harris, PhD (503)
494-8942
RISKS AND DISCOMFORTS:
The main risk is fatigue of the children being tested due to the amount of time needed to complete the
testing sessions. Because attention and concentration will be needed from your child, breaks will be
allowed between tests. Additional visits may be scheduled if needed to complete all of the tests within 3
months. Children may stop testing at any time.
If the results of these studies of your child’s genetic makeup were to be released through a breach of
confidentiality, this could affect your child’s ability to get insurance or to get or keep a job.
Your child may feel some pain when the blood is drawn. There is a small chance the needle will cause
bleeding, a bruise, or an infection. Your child may cry or become angry. Your child may be fearful of
blood draws in the future.
SUBJECT ACCESS TO RESEARCH INFORMATION:
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The results of your child’s genetic testing in these studies will not be made available to you because the
research is still in an early phase and the reliability of the results is unknown. However, a written report
detailing your child’s neruopsychological profile will be provided at no cost.
BENEFITS:
Your child will not personally benefit from being in this study. However, by serving as a subject, your
child may help us learn how to benefit patients in the future.
ALTERNATIVES:
You may choose not to participate in this study at all, or you may choose to participate in the cholesterol
measurement and genetic testing portions, but not to have DNA stored for future genetic testing.
CONFIDENTIALITY:
We will not use your name or your identity for publication or publicity purposes. All the information
gathered will be coded with a unique identifier. Only study personnel will have access to identifying
information.
Research records may be reviewed and copied by the sponsor (the Northwest Health Foundation), the
OHSU Institutional Review Board, the Office for Human Research Protections (OHRP), the Oregon
Clinical and Translational Research Instituted (OCTRI), and the National Center for Research Resources
(NCRR).
Please note that under Oregon Law, suspected child abuse must be reported to appropriate authorities.

COSTS:
There will be no cost to you for participating in this research.
LIABILITY:
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If you believe you have been injured or harmed while participating in this research and require immediate
treatment, contact Michael Harris, PhD (503) 494-8942.

You have not waived your legal rights by signing this form. If you are harmed by the study
procedures, you will be treated. Oregon Health & Science University does not offer to pay for
the cost of the treatment. Any claim you make against Oregon Health & Science University may
be limited by the Oregon Tort Claims Act (ORS 30.260 through 30.300). If you have questions
on this subject, please call the OHSU Research Integrity Office at (503) 494-7887.
The Northwest Health Foundation does not offer compensation for injury. It is not the policy of
the U.S. Department of Health and Human Services to compensate or provide medical treatment
for human subjects in the event the research results in physical injury.
Oregon Health & Science University is subject to the Oregon Genetic Privacy law (ORS 192.531
through ORS 192.549) and its requirements concerning confidentiality and the legal remedies
provided by that law for breach of its requirements. You have not waived your legal rights by
signing this form. For clarification on this subject, or if you have questions, please call the
OHSU Research Integrity Office at (503) 494-7887.
PARTICIPATION:
If you have any questions regarding your rights as a research participant, you may contact the OHSU
Research Integrity Office at (503) 494-7887.
You do not have to join this or any research study. If you do join, and later change your mind, you may
withdraw at any time. If you refuse to join or withdraw early from the study, there will be no penalty or
loss of any benefits to which you are otherwise entitled.
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Your child’s health care provider may be one of the investigators of this research study, and as an
investigator is interested in both your child’s clinical welfare and in the conduct of this study. Before
entering this study or at any time during the research, you may ask for a second opinion about your care
from another doctor who is in no way involved in this project.
If in the future you decide you no longer want to participate in this research, we will destroy all your
child’s blood/genetic samples as well as information from your child’s medical record. However, if your
child’s genetic samples or information are already being used in an on-going research project and if their
withdrawal jeopardizes the success of the entire project, we may ask to continue to use them until the
project is completed.
Your	
  child	
  may	
  be	
  removed	
  from	
  the	
  study	
  if	
  the	
  investigator	
  stops	
  the	
  study,	
  or	
  if	
  the	
  sponsor	
  
stops	
  the	
  study.	
  We will give you a copy of this form.
SIGNATURES: Your signature below indicates that you have read this entire form and agree to have
your child participate in the study detailed above.
(Please initial where appropriate)
________

I give my consent for my child’s blood/DNA samples to be used for this study only.

________

I give my consent for my child’s blood/DNA samples to be used for this study and stored
for possible use in future studies of autism or related disorders, but I wish to be
contacted for permission prior to any future use.

________

I give my consent for my child’s blood/tissue samples to be used for this and future
studies of autism or related developmental disorders, and do not need to be contacted
for permission in the future.
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OREGON HEALTH & SCIENCE UNIVERSITY
INSTITUTIONAL REVIEW BOARD
PHONE NUMBER (503) 494-7887	
  
CONSENT/AUTHORIZATION FORM APPROVAL DATE
	
  

Mar.	
  18,	
  2009	
  
	
  

Do	
  not	
  sign	
  this	
  form	
  after	
  the	
  Expiration	
  
date	
  of:	
  	
  	
  3/17/2010	
  

Parent/Guardian’s Signature

Date

Parent/Guardian’s Printed Name and Relationship to Child (such as “foster parent”)
	
  
Signature of Person Obtaining Consent
Printed Name of Person Obtaining Consent

Date
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Demographics
Please circle the response that best represents you and your family.
1. What is the sex of your child?

a. male

2. Highest level of education completed:
a. High school
b. Vocational or Technical College
c. Bachelor’s Degree
d. Graduate Degree
e. Some College
3. What do you consider to be your ethnicity?
a. White/Non-Hispanic
b. Hispanic
c. Asian/Pacific Islander
d. African American
e. American Indian
f. Other

b. female

81

Determining the Clinical Utility of M-P-R Scales
	
  

Appendix E
Curriculum Vita

82

Determining the Clinical Utility of M-P-R Scales
	
  

Meaghan E. Peters
Curriculum Vitae
740 Warm Springs Ave.
Boise, ID 83712
(208) 343-7797
mpeters@childrenshomesociety.com

EDUCATION
2007-2013

Doctoral Candidate, Clinical Psychology
George Fox University, Newberg, OR
Dissertation: Determining the Clinical Utility of the MerrillPalmer-Revised Scales of Development in a Sample of Children
with Autistic Disorder.
Committee Members: Wayne Adams, Ph.D. ABPP., Trevor Hall,
PsyD., Kathleen Gathercoal, Ph.D.

2007

Master of Arts, Clinical Psychology
George Fox University, Newberg, OR

2000

Bachelor of Arts, Psychology, Cum Laude
Trinity International University, Deerfield, IL
HONORS AND AWARDS

April 2008

Richter Research Award Grant
Determining the Clinical Utility of the Merrill Palmer Revised
Scales of Development on an Autistic population.
Role: Principal Investigator
Funding Period: April 2007-Dec 2009, $1,896

August 2004

Richter Research Travel Award
Present research at professional conference.
Funding period: August 2004, $1,500

April 2003

Richter Research Award Grant
Establish a baseline for guessing on recognition tasks of the Wide
Range Assessment of Memory and Learning- 2nd Edition.
Role: Principal Investigator
Funding period: April 2003-April 2004, $3,500.

May 1999

Elected Psi-Chi Honor Society President
Trinity International University
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Funding period: April 2003-April 2004, $3,500.
May 1999

January 2012Present

September 2011December 2011

August 2010August 2011

Elected Psi-Chi Honor Society President
Trinity International University
CLINICAL EXPERIENCE
Psychometrician
Warm Springs Counseling Center
Boise, ID
Supervisor: Brett Thomas, Ph.D.
Conducting comprehensive psychological evaluations for children and
adolescents seeking a medical diagnosis
Psychometrician
Northwest Neurobehavioral Health
Meridian, ID
Supervisor: Trevor Hall, Psy.D.
Conducted neuropsychological assessments for children and adolescents seeking
a medical diagnosis.
APA Accredited Pre-Doctoral Internship
Warm Springs Counseling Center
Boise, Idaho
Supervisor: Carolyn Golden, Psy.D.
Conducted neurobehavioral assessments for children and adolescents seeking a
medical diagnosis. Provided individual, family, and group therapy.

July 2009June 2010

Multidisciplinary Autism Clinic Practicum
Oregon Health and Science University, Portland, OR
Supervisor: Darryn Sikora, Ph.D.
Conduced cognitive and autism related assessments for children referred to the
autism clinic seeking a medical diagnosis. Provided feedback and
recommendations to families.

September 2007May 2008

School-based Assessment Practicum
North Marion School District, Aurora, OR
Supervisor: Susan Patchin, Psy.D.
Conducted cognitive and academic assessment for students grade K-12 for the
purpose of special education eligibility.

September 2007Present

	
  

	
  
Vocational Rehabilitation/ Educational Assessment Practica
Forest Grove, OR
Supervisor: Susan Patchin, Psy.D.
Conducted vocational assessments for an adult vocational rehabilitation training
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program and psycho-educational assessments for a local university for the
purpose of detecting learning disabilities.
	
  
Residential/Day Treatment Practica
August 2003-May Edgefield Children’s Center, Troutdale, OR
2004
Supervisors: Kelli Peligreni, Psy.D., and Freda Manning, Psy.D.
Conducted intake and academic assessments. Provided individual play therapy
and group therapy for residential and day treatment students grade K-8 with a
range of mental health problems (bipolar disorder, oppositional defiant
disorder, ADHD, conduct disorder, schizophrenia, anxiety disorders, mood
disorders). Participated in IEP evaluations and classroom consultation.
Received training and supervision in the use of play therapy and behavior
management strategies.
Supplemental Residential/School Practica
May 2003-August Yellowstone Boys and Girls Ranch, Billings, MT
2003
Supervisors: Phil House, Psy.D., and Loretta Sand, M.A.
Provided individual, family, and group therapy for boys ages 10-15 living in a
residential home with a range of mental health problems (mood disorders,
anxiety disorders, bipolar disorder, conduct disorder, oppositional defiant
disorder, mental retardation, PTSD). Also facilitated experiential hiking trips
and horse therapy. Conducted intake assessments, cognitive assessments, and
IEP evaluations. Received training and supervision in the use of play therapy,
horse therapy, and behavior management strategies.

	
  

	
  
School-based Practica
August 2002-May Archer Glen Elementary, Sherwood, OR
2003
Supervisor: Hannah Stere, Psy.D.
Conducted academic assessment and classroom observations. Participated in
student assistance team meetings and weekly teacher consultation. Provided
individual and group therapy for students grade K-5 with a range of mental
health problems (anxiety disorders, mood disorders, ADHD, autism spectrum
disorder, and behavior disorders). Groups focused on anger management, social
skill building, and grief support. Received supervision in the use of play therapy
and behavior management.

Psychology Trainee
August 2002-May George Fox University Health and Counseling Center, Newberg, OR
2003
Supervisors: Carol Dell’ Oliver, Ph.D., and Brad Garner, M.A.
Provided individual psychotherapy to university students, one male and one
female. Conducted personality assessments, developed treatment plans, and
participated in case presentations to supervision group.
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SUPERVISION EXPERIENCE
September 2010August 2011

	
  
Psychosocial Rehabilitation Specialist Supervisor
Warms Springs Counseling Center, Boise, ID
Conducted group supervision for PSR specialists. Provided training surrounding
relevant diagnostic material, consulted on individual cases, and oversaw
treatment planning.

Student Therapist Overseer
January 2008-May George Fox University, Newberg, OR
2008
Supervisor: Mary Peterson, Ph.D
Provided supervision and feedback for a first year graduate student. Offered
assistance with intake interview strategies, treatment planning, and behavior
strategies with an undergraduate population.
September 2007May 2008

Student Therapist Supervisor
George Fox University, Newberg, OR
Supervisor: Mary Peterson, Ph.D.
Provided supervision and feedback for a second year graduate student. Offered
behavior strategies, assistance with treatment planning, and clarification of
diagnosis with student working with adult clients at a community mental health
setting.
RELAVENT WORK EXPERIENCE

	
  

	
  
Child Development Specialist, .5 FTE paid position
October 2004-June Archer Glen Elementary, Sherwood, OR
2005
Oregon Child Development Specialist Certification
Supervisor: Pete Miller, Principal
Provided individual and group therapy to students K-5 with a variety of mental
health disorders (anxiety disorder, mood disorder, autism spectrum disorder,
ADHD, adjustment disorder). Implemented Steps to Respect, an anti-bullying
campaign, and mentored a fifth grade leadership team. Conducted academic
assessments for IEP evaluations and created 504 plans.
	
  

May 2002-May
2004

Camp Manager, Summer full-time paid position
Universal Cheerleading Association, Memphis, TN
Supervised the production of Jr/Sr high school cheerleading camps throughout
Oregon, Washington, Idaho, and California. Acted as a liaison between the
company and the host university to ensure successful camps with an average of
250 campers and 20 staff. Was on call 24 hours a day attending to behavior
issues, physical injuries, and supporting a positive atmosphere for participants.
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S.M.A.R.T. Program Coordinator, .5 FTE paid position
Oregon Children’s Foundation, Portland, OR
October 2000-May Recruited, trained, and supervised 40 adult volunteers to act as reading coaches
2002
to children grades K-3. Established positive communication efforts between
school officials and the Oregon Children’s Foundation.
	
  

RESEARCH EXPERIENCE
September 2007Present; August
2002-May 2004

July 2008-June
2010

Research Vertical Team Member
George Fox University, Graduate Department of Clinical Psychology
Newberg, OR
Participated in bimonthly meetings which discussed ongoing research projects
focusing on assessment of children. Literature reviews were presented and
consultation with respect to methodology, statistical analysis, and idea
clarification.
Supervisor: Wayne Adams, Ph.D., ABPP

	
  

Study Coordinator
Title: Possible role of cholesterol metabolism in the etiology of autism, and
correlates with neurocognitive/neurobehavioral phenotype
Principal Investigator: Michael Harris, Ph.D.
Project Mentor: Robert Steiner, MD.
Responsible for recruiting and scheduling project participants, administering the
Merrill-Palmer-R to children aged 2-6, the Vineland Behavior Adaptive Scale-II,
Child Behavior Checklist, and the PDDBI. Also manage coding and data entry.
	
  

June 2008Februray 2009

June 2008November 2008

Research Assistant
Pediatric Pain Management Center, Oregon Health and Science University,
Department of Anesthesiology and Peri-Operative Medicine, Portland, OR.
Advisors: Tonya Palermo, Ph.D., and Anna Wilson, Ph.D.
Currently assisting with study coordination of a study examining the effects of a
Web-based Cognitive Behavioral treatment program for adolescents ages 11-17
years with chronic pain. Assisting with participant recruitment, data
management, and contacting project participants.
Research Assistant
Title: The relationship between cholesterol metabolism and autism.
Principal Investigator: Darryn Sikora, Ph.D.
Assisted with recruitment and scheduling project participants.
	
  

Research Assistant
June 2005-August Title: Administering the Wide Range Assessment of Memory and Learning-2
2005
with an ADHD population.
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Principal Investigator: Robert Weniger, Psy.D
Administered the WRAML-2 to participants in conjunction with CBCL.
	
  

April 2003November 2004

Research Leader
Title: Establishing a baseline for guessing using the WRAML-2 recognition
subtests.
Advisor: Wayne Adams, Ph.D., ABPP
First authored project designed to establish a baseline for guessing on the
recognition memory subtests of the Wide Range Assessment of Memory and
Learning-2nd Edition. Intent was to determine the likelihood of guessing on
recognition tasks if those tasks had not been previously presented for the purpose
of detecting malingering. Presented poster of findings at the 2004 APA
convention in Honolulu, HI, and at the 2004 NAN Convention in Seattle, WA.
TEACHING EXPERIENCE

March 2003

Guest Lecturer
Undergraduate Department of Psychology, George Fox University
Newberg, OR
PSY 130 Introduction to Psychology. Presented a lecture on emotion and
motivation.

	
  

	
  

April 2003

Guest Lecturer
Undergraduate Department of Psychology, George Fox University
Newberg, OR
PSY 381 Counseling
Presented a lecture on Coping
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Teaching Assistant
Undergraduate Department of Psychology,
Trinity International University, Deerfield, IL
Taught a freshman level course on the college adjustment process. Facilitated
discussion surrounding adjustment and offered supportive techniques.
Advisor: Timothy Robinson, Ph.D.
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2007-Present
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APAGS Representative
May 2003-August Served as liaison between APA and student body, responsible for membership
2004
renewal, and provided support to graduate students.
Division 54 Student Recruiter
May 2003-August Increased student awareness of society and recruited student members of
2004
Pediatric Psychology
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Palermo, T.M., Long, A.C., Peters, M., Lewandowski, A., & Somhegyi, H. (2009). Randomized
controlled trial of an Internet-delivered family cognitive-behavioral therapy intervention for children
and adolescents with chronic pain. PAIN, 146, 205-213.
	
  

POSTER PRESENTATIONS
Kriz, D., Peters, M. & Hall, T. (2011, January) The Importance of Neuropsychological
Evaluation in Mild TBI: A Pediatric Case Example. Poster Presented at the Pacific Nortwest
Brain Injury Association Annual Conference, Portland, Oregon.
McGee (Peters), M., Weniger, R., & Adams, W. (2004, August) Establishing a baseline for
guessing using the WRAML-2 recognition subtests. Poster Presented at the American
Psychological Association Conference, Honolulu, HI.

Determining the Clinical Utility of M-P-R Scales
PROFESSIONAL REFERENCES
Current Supervisor:
Brett Thomas, Ph.D.
Warm Springs Counseling Center
740 Warm Springs Ave.
Boise, Idaho 83712
(208) 343-7797
Internship Training Director:
Carolyn Golden, PsyD
2076 S. Eagle Rd.
Meridian, ID 83642
(208)-955-7333
Primary Graduate Advisor:
Wayne Adams, Ph.D., ABPP
414 N. Meridian St. #V 104
Newberg, OR 97132
(503) 554-2372

	
  

90

